

R E M A R K S

Applicants respectfully request entry of the above preliminary amendment.

Pursuant to 35 U.S.C. § 120, the specification has been amended to recite the divisional status of this application, and its relationship to previous applications filed by Applicants. The specification has also been amended to add sequence identifiers and to include a substitute paper copy of the Sequence Listing in conformance with 37 C.F.R. §§ 1.821-1.825. Applicants' amendments do not introduce new matter.

In the prior application Serial No. 09/09/150,867 (our File No. UCSD-04734), the claims were restricted Office Action mailed on 7/9/99, the Examiner restricted the claims into five Groups, as follows:

- Group I: Claims 1-11 and 36-38, drawn to CENP-E polypeptides and kits comprising them;
- Group II: Claims 12-15 and 39, drawn to polynucleotides which encode CENP-E polypeptides and to method of making a protein recombinantly;
- Group III: Claim 16, drawn to an antibody which binds to *Xenopus* CENP-E;
- Group IV: Claims 17-35, drawn to methods for identifying a agent which modulates CENP-E activity; and
- Group V: Claims 40-42, drawn to method of moving microtubules in a plus-ended direction.


This application presents for prosecution Group IV (Claims 17-35).

Claims 1-11 and 36-38 (Group I) have been cancelled as they are currently being prosecuted in co-pending application No. 09/150,867 (our File No. UCSD-04734). Claims 12-15 and 39 (Group II) have been cancelled as they are currently being prosecuted in co-

pending application No. 09/724,584 (our File No. UCSD-04870). Claims 16 and 40-42 have been cancelled without prejudice to their prosecution in another application.

Signed on behalf of:

Dated: August 27, 2003


Maha A. Hamdan
Registration No. 43,655
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
(415) 904-6500